Low-Dose Naltrexone, an Opioid-Receptor Antagonist, is a Broad-Spectrum Analgesic: A Retrospective Cohort Study

References

• SAMHSA. Key substance use and mental health indicators in the United States: results from the 2018 national survey on drug use and health (2019). www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR1PDFW090120.pdf
   Google Scholar
• HEAL Initiative Research Plan . National Institutes of Health (2021). https://heal.nih.gov/about/research-plan#references
   Google Scholar
• Nahin R . Estimates of pain prevalence and severity in adults: United States, 2012. J. Pain16(8), 769–780 (2015).
   PubMed Web of Science ®Google Scholar
• Parker C , NguyenT , SegalD , MacDonaldM , ChandeN. Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.4, CD010410 (2018).
   PubMedGoogle Scholar
• Smith J , BingamanS , RuggieroFet al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig. Dis. Sci.56(7), 2088–2097 (2011).
   PubMed Web of Science ®Google Scholar
• Lie M , vander Giessen J , FuhlerGet al. Low dose naltrexone for induction of remission in inflammatory bowel disease patients. J. Transl. Med.16(1), 55 (2018).
   PubMedGoogle Scholar
• Cree B , KornyeyevaE , GoodinD. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann. Neurol.68(2), 145–150 (2010).
   PubMed Web of Science ®Google Scholar
• Sharafaddinzadeh N , MoghtaderiA , KashipazhaD , MajdinasabN , ShalbafanB. The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial. Mult. Scler.16(8), 964–969 (2010).
   PubMed Web of Science ®Google Scholar
• Gironi M , Martinelli-BoneschiF , SacerdotePet al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult. Scler.14(8), 1076–1083 (2008).
   PubMed Web of Science ®Google Scholar
• Rahn K , McLaughlinP , ZagonI. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: therapeutic implications for multiple sclerosis. Brain Res.1381, 243–253 (2011).
   PubMed Web of Science ®Google Scholar
• Younger J , MackeyS. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med.10(4), 663–672 (2009).
   PubMed Web of Science ®Google Scholar
• Younger J , NoorN , McCueR , MackeyS. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum.65(2), 529–538 (2013).
   PubMed Web of Science ®Google Scholar
• Metyas S , YeterK , SolymanJ , ArkfeldD. AB0658 low dose naltrexone in the treatment of fibromyalgia. Ann. Rheum. Dis.72, A990 (2013).
   Web of Science ®Google Scholar
• Parkitny L , YoungerJ. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines5(2), doi:10.3390/biomedicines5020016 (2017).
   PubMed Web of Science ®Google Scholar
• Raknes G , SmåbrekkeL. Low dose naltrexone: effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS ONE14(2), (2019).
   Web of Science ®Google Scholar
• Zashin S . Sjogren’s syndrome: clinical benefits of low-dose naltrexone therapy. Cureus11(3), e8948 (2019).
   Web of Science ®Google Scholar
• Tran T , ChenA , WorswickS. Successful treatment of dermatomyositis with low-dose naltrexone. Dermatol. Ther.31(6), e12720 (2018).
   PubMed Web of Science ®Google Scholar
• Chopra P , CooperM. Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). J. Neuroimmune Pharmacol.8(3), 470–476 (2013).
   PubMed Web of Science ®Google Scholar
• Kim P , FishmanM. Low-dose naltrexone for chronic pain: update and systemic review. Curr. Pain Headache Rep.24(10), 64 (2020).
   PubMed Web of Science ®Google Scholar
• Ji R , NackleyA , HuhY , TerrandoN , MaixnerW. Neuroinflammation and central sensitization in chronic and widespread Pain. Anesthesiology129(2), 343–366 (2018).
   PubMed Web of Science ®Google Scholar
• Latremoliere A , WoolfC. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain.10(9), 895–926 (2009).
   PubMed Web of Science ®Google Scholar
• Harte S , HarrisR , ClauwD. The neurobiology of central sensitization. J. Appl. Behav. Res.23, (2018).
   PubMedGoogle Scholar
• Dasu M , DevarajS , ZhaoL , HwangD , JialalI. High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes57(11), 3090–3098 (2008).
   PubMed Web of Science ®Google Scholar
• Woolard M , KevilC. Paying the toll for glucose regulation: a central role for TLR3. Diabetes.64(10), 3345–3346 (2015).
   PubMed Web of Science ®Google Scholar
• Fischer M , EhlersM. Toll-like receptors in autoimmunity. Ann. N. Y. Acad. Sci.1143, 21–34 (2008).
   PubMed Web of Science ®Google Scholar
• Mifflin K , KerrB. Pain in autoimmune disorders. J. Neurosci Res.95(6), 1282–1294 (2017).
   PubMed Web of Science ®Google Scholar
• Nicotra L , LoramLC , WatkinsLR , HutchinsonM. Toll-like receptors in chronic pain. Exp. Neurol.234(2), 316–329 (2012).
   PubMed Web of Science ®Google Scholar
• Lee M , SilvermanS , HansenH , PatelV , ManchikantiL. A comprehensive review of opioid-induced hyperalgesia. Pain Physician14(2), 145–161 (2011).
   PubMed Web of Science ®Google Scholar
• Low Y , ClarkeCF , HuhBK. Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med. J.53(5), 357–360 (2012).
   PubMed Web of Science ®Google Scholar
• Samuelsen P , NielsenC , WilsgaardT , StubhaugA , SvendsenK , EggenA. Pain sensitivity and analgesic use among 10,486 adults: the Troms⊘study. BMC Pharmacol. Toxicol.18(1), 45 (2017).
   PubMedGoogle Scholar
• Hooten W , MantillaC , SandroniP , TownsendC. Associations between heat pain perception and opioid dose among patients with chronic pain undergoing opioid tapering. Pain Med.11(11), 1587–1598 (2010).
   PubMed Web of Science ®Google Scholar
• Belkin M , ReinheimerH , LevyJ , JohnsonB. Ameliorative response to detoxification, psychotherapy, and medical management in patients maintained on opioids for pain. Am. J. Addict.26(7), 738–743 (2017).
   PubMed Web of Science ®Google Scholar
• Cunningham J , EvansM , KingS , GehinJ , LoukianovaL. Opioid tapering in fibromyalgia patients: experience from an interdisciplinary pain rehabilitation program. Pain Med.17(9), 1676–1685 (2016).
   PubMed Web of Science ®Google Scholar
• Roeckel L , LeCoz G , Gavériaux-RuffC , SimoninF. Opioid-induced hyperalgesia: cellular and molecular mechanisms. Neuroscience338, 160–182 (2016).
   PubMed Web of Science ®Google Scholar
• Oaks Z , StageA , MiddletonB , FaraoneS , JohnsonB. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. Discov. Med.26(144), 197–206 (2018).
   PubMed Web of Science ®Google Scholar
• Blausen Medical. Medicalgallery of Blausen Medical 2014. WikiJournalof Medicine1(2), doi:10.15347/wjm/2014.010 ISSN 2002-4436 (2014).
   Google Scholar
• Takeuchi O , AkiraS. Pattern recognition receptors and inflammation. Cell140, 805–820 (2010).
   PubMed Web of Science ®Google Scholar
• Zhang X , CuiF , ChenHet al. Dissecting the innate immune recognition of opioid inactive isomer (+)-naltrexone derived Toll-like receptor 4 (TLR4) antagonists. J. Chem. Inf. Model.58(4), 816–825 (2018).
   PubMed Web of Science ®Google Scholar
• Wang X , ZhangY , PengYet al. Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br. J. Pharmacol.173(5), 856–869 (2016).
   PubMed Web of Science ®Google Scholar
• Cant R , DalgleishA , AllenR. Naltrexone inhibits IL-6 and TNFα production in human immune cell subsets following stimulation with ligands for intracellular Toll-like receptors. Front. Immunol.8, 809 (2017).
   PubMed Web of Science ®Google Scholar
• Hutchinson M , ZhangY , BrownKet al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur. J. Neurosci.28(1), 20–29 (2008).
   PubMed Web of Science ®Google Scholar
• Ellis A , WieselerJ , FavretJet al. Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. J. Pain15(4), 407–421 (2014).
   PubMed Web of Science ®Google Scholar
• Dieckmann G , OzmenM , CoxS , EngertR , HamrahP. Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain. Ocul. Surf.20, 33–38 (2021).
   PubMed Web of Science ®Google Scholar
• Srinivasan A , DuttaP , BansalD , ChakrabartiA , BhansaliA , HotaD. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J. Diabetes.13(10), 770–778 (2021).
   PubMed Web of Science ®Google Scholar
• Ong C , LirkP , TanCet al. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin. Med. Res.5(1), 19–34 (2007).
   PubMedGoogle Scholar
• Brown M , BussellJ. Medication adherence: WHO cares?. Mayo Clin. Proc.86(4), 304–314 (2011).
   PubMed Web of Science ®Google Scholar
• Romero-Sandoval E , SweitzerS. Nonneuronal central mechanisms of pain: glia and immune response. Prog. Mol. Biol. Transl. Sci.131, 325–358 (2015).
   PubMed Web of Science ®Google Scholar
• Selfridge B , WangX , ZhangYet al. Structure-activity relationships of (+)-naltrexone-inspired Toll-like receptor 4 (TLR4) antagonists. J. Med. Chem.58(12), 5038–5052 (2015).
   PubMed Web of Science ®Google Scholar